In-Depth Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Report: Business Trends, Growth Factors, and Forecast to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Heading Into 2029?
In recent times, there has been substantial growth in the market size of asthma and chronic obstructive pulmonary disease (copd) drugs. The market, which is expected to climb from $32.52 billion in 2024 to $35.66 billion in 2025, will do so at a compound annual growth rate (CAGR) of 9.6%. Factors contributing to growth during the historic period include an increase in air pollution, escalated tobacco smoking rates, heightened awareness regarding respiratory illnesses, widespread use of corticosteroids and bronchodilators, and an increase in healthcare spending.
In the next few years, the market size for asthma and chronic obstructive pulmonary disease (copd) medication is slated to experience robust growth. The market is predicted to reach $50.99 billion in 2029, boasting a compound annual growth rate (CAGR) of 9.4%. The spike in growth throughout the forecast period can be attributed to factors such as the surging demand for customized medicine, the rise in biologics and advanced therapies adoption, the increasing incidence of environmental allergies, escalating clinical trials and approvals, and the growing concern of non-communicable diseases. Key trends moving forward include the rise of technologically-advanced smart inhalers, the development of dual-action bronchodilators, the integration of electronic health records (EHR) and drug data, advancements in biopharmaceutical molecules and the incorporation of machine learning for drug discovery.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24472&type=smp
Which Factors Are Pushing The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market Forward?
The soaring rates of tobacco usage are predicted to boost the expansion of the asthma and COPD drugs market in the future. The term smoking denotes the practice of using tobacco goods by inhaling the resultant smoke, and this can precipitate grave health conditions like lung cancer and heart disease. The surging rates of smoking are largely influenced by societal pressure, where peer influence, traditional norms, and social surroundings are prompting individuals to commence and maintain smoking. Drugs used to treat asthma and chronic obstructive pulmonary disease (COPD) work to lessen the respiratory impairment caused by smoking through the reduction of inflammation, the relaxation pulmonary muscles, and the enhancement of air circulation, thereby relieving symptoms and boosting lung functionality. For instance, a 2024 study on trends in smoking among younger individuals by the Switzerland-based non-profit entity, the European Respiratory Society (ERS), revealed a significant uptick in smoking rates, climbing from 22.5% of participating respondents in 2022 to 40.1% in 2024. Consequently, the rising rates of tobacco usage are fueling the expansion of the asthma and COPD drugs market.
Which Segment Held The Largest Share In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Market In 2025?
The asthma and chronic obstructive pulmonary disease (COPD) drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers
2) By Route Of Administration: Inhalation, Oral, Injection, Nasal, Other Route Of Administrations
3) By Patient Group: Adult, Pediatric, Geriatric
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
Subsegments
1) By Bronchodilators: Short-Acting Beta-2 Agonists (SABA), Long-Acting Beta-2 Agonists (LABA), Anticholinergics, Long-Acting Muscarinic Antagonists, Methylxanthines
2) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Intravenous Corticosteroids
3) By Combination Drugs: Long-Acting Beta-Agonist + Inhaled Corticosteroid, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist, Long-Acting Beta-Agonist + Long-Acting Muscarinic Antagonist + Inhaled Corticosteroid
4) By Leukotriene Modifiers: Leukotriene Receptor Antagonists, Leukotriene Synthesis Inhibitors
How Are Key Trends Driving Expansion In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?
The asthma and COPD drugs market is experiencing a shift as key players concentrate their efforts on creating novel arrangements such as fixed-dose combination (FDC) drugs, with the aim of enhancing patient compliance and medicinal effectiveness. FDC drugs contain multiple active constituents in a unified dose, and can contribute to managing asthma and COPD more effectively by coupling bronchodilators with anti-inflammatory agents, which optimizes symptom regulation and patient consistency. In June 2022, Glenmark Pharmaceuticals Limited, a pharmaceutical firm based in India, initiated the release of Indamet, an innovative FDC medication comprising Indacaterol, a long-term beta-agonist (LABA), and Mometasone Furoate, an inhaled corticosteroid (ICS), to treat unregulated asthma. Indamet represents the first FDC of its type to be sanctioned by India’s Drug Controller General (DCGI) for introduction into the Indian market. It comes in three potencies, i.e., Indacaterol 150 mcg combined with Mometasone 80 mcg, 160 mcg, or 320 mcg to be administered once a day. This concoction aims to enhance lung performance, better symptom management, lower occurrences of exacerbations, and uplift treatment adherence in adults and teenagers aged 12 years and above.
Which Organizations Are Driving Progress In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?
Major companies operating in the asthma and chronic obstructive pulmonary disease (COPD) drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, Aurobindo Pharma
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Industry?
North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma and chronic obstructive pulmonary disease (COPD) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24472&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
